Novo Nordisk faces a pivotal Q1 earnings test amid share buybacks, pipeline diversification beyond semaglutid, and cautious analyst forecasts. Stock down 14% YTD.<\/p>\n
The Danish drugmaker is attempting to rewrite its narrative on multiple fronts, but the numbers due Wednesday morning will determine whether the market buys the story.<\/p>\n
Novo Nordisk has been busy behind the scenes. On Tuesday, the company confirmed it had snapped up nearly 14.8 million of its own B-shares for roughly 3.8 billion Danish kroner, hoovering up 0.7 percent of its share capital in the first tranche of a buyback program that is set to expand significantly this year. The move has provided a modest floor under the stock, which has clawed back about nine percent over the past week to trade at \u20ac38.38. Still, the shares remain roughly 14 percent in the red since January 1.<\/p>\n
That share price recovery faces its sternest test at 7:30 a.m. CET on Wednesday, when Novo Nordisk releases its first-quarter results for 2026. Analysts are penciling in operating profit of around 29 billion Danish kroner, with consensus revenue estimates sitting at $11.13 billion and earnings per share at $0.87. The company has historically impressed with cost discipline but has missed top-line targets on multiple occasions \u2014 a pattern that has left sell-side sentiment decidedly cautious.<\/p>\n
Bernstein Research recently initiated coverage with an \u201cunderperform\u201d rating and a price target of just 175 Danish kroner, while Citigroup trimmed its own target to 275 kroner while maintaining a neutral stance. Should management reaffirm its gloomy full-year guidance \u2014 which calls for a five to 13 percent decline in both revenue and operating profit \u2014 the stock could find itself testing the chart support at its 52-week low of \u20ac30.48.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n Beyond Semaglutid: A Pipeline in Transition<\/p>\n The company is acutely aware that its dependence on semaglutid \u2014 the active ingredient behind Ozempic and Wegovy \u2014 has become a vulnerability. Patent expirations in international markets are already weighing on the outlook, and competitive pressure from Eli Lilly is intensifying. The American rival recently smashed expectations with Mounjaro and Zepbound and raised its own annual forecast.<\/p>\n Novo Nordisk is therefore pushing hard to diversify. On the same day it reports earnings, the company has launched a Phase 1 clinical trial for LX9851, an oral drug candidate targeting obesity and metabolic diseases, developed in partnership with Lexicon Pharmaceuticals. The deal includes potential milestone payments of up to $1 billion to Lexicon \u2014 a clear statement of intent that Novo Nordisk is willing to spend heavily to build a pipeline beyond its current blockbusters.<\/p>\n Researchers are also investigating whether semaglutid itself can reduce alcohol consumption in patients with alcohol use disorder. Because the drug is already approved, no new regulatory filing would be required, and development costs would be modest.<\/p>\n The Ozempic Pill Hits US Pharmacies<\/p>\n The most immediate test of Novo Nordisk\u2019s ability to defend its turf, however, is the newly reformulated oral semaglutid tablet that hit US pharmacies on May 4. Marketed internally as the \u201cOzempic pill,\u201d the product is approved for adults with type 2 diabetes, offering improved blood sugar control and a reduced risk of major cardiovascular events. It is manufactured exclusively in the US and distributed through a network of more than 70,000 pharmacies.<\/p>\n Investors will be scrutinizing early sales data from this launch with particular intensity, given that the FDA approved a high-dose version of Wegovy in March 2026 \u2014 another defensive move to shore up the company\u2019s market position. But Eli Lilly is applying relentless pressure in the oral weight-loss space, and the competitive dynamics are only getting tougher.<\/p>\n